Related Experiment Video
Updated: Jun 16, 2026
06:28
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
Acute myeloid leukemia after infliximab: a case report
F Kemta Lekpa1, K Zahra, C Pautas
1Rheumatology Department, Henri Mondor Hospital, Paris XII University, Créteil, France.
Clinical and Experimental Rheumatology
|February 13, 2010
Summary
The risk of certain cancers, like acute myeloid leukemia, may be associated with TNF-alpha antagonists used for inflammatory conditions. Further research is needed to confirm a causal link between these treatments and cancer development.
Area of Science:
- Oncology
- Immunology
- Rheumatology
Background:
- Tumor necrosis factor-alpha (TNF-α) antagonists are used to treat chronic inflammatory diseases.
- Concerns exist regarding a potential increased risk of malignancies, including lymphoproliferative disorders, in patients receiving TNF-α antagonists.
- The causal relationship between TNF-α antagonist therapy and cancer development remains uncertain.
Observation:
- A 60-year-old male patient with ankylosing spondylitis was undergoing treatment with infliximab.
- The patient developed acute myeloid leukemia (AML) while on infliximab therapy.
Findings:
- This case report documents the occurrence of acute myeloid leukemia in a patient treated with infliximab for ankylosing spondylitis.
- The temporal association suggests a possible link, warranting further investigation.
Implications:
- This case highlights the need for vigilance regarding potential oncogenic risks associated with TNF-α antagonist therapy.
- Further epidemiological studies and research are crucial to elucidate the relationship between TNF-α inhibitors and the development of hematologic malignancies.
- Clinicians should consider this potential risk when managing patients with chronic inflammatory diseases on TNF-α antagonists.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...